Former Teva boss Israel Makov appointed non-executive chairman Dilip Shanghvi is known for his contrarian bets. In the 1980s, while Indian companies were hawking antibiotics and other short-term treatments to general physicians, Shanghvi started selling medicines for chronic diseases to specialists. There have been many other such instances since then. On Tuesday, he parted ways with conventional wisdom
Business tycoon Mukesh Ambani has retained his title of being the world's richest Indian, despite an erosion of $4.7 billion in his wealth in the past year as he beat 47 billionaires from India in
India’s most valuable pharma company, Sun Pharmaceutical Industries’ stock is up two per cent over the past two days, following better than expected results. While gains from Taro led
While Sun Pharma has delivered robust growth so far, effective utilisation of its $1 billion cash for acquisitions can help propel growth.
Sun Pharma chairman Dilip Shanghvi will pick up an 11 per cent stake in an Israeli investment company that specialises in the life sciences sector. The investment, to be carried out in his personal
Sun Pharmaceutical Industries Ltd. reported a 32 per cent growth in its net profit for year ending March 31, 2011 at Rs 1816 crore. Net sales from operations reported at Rs 5721 crore, grew by 43
Site optimized for Internet Explorer 5.5 and above.
See Disclaimer |Privacy Policy &Parental Guidance on pornography |careers@sify |About Us |Feedback |Advertise